PMID- 34687376
OWN - NLM
STAT- MEDLINE
DCOM- 20211029
LR  - 20220114
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 23
IP  - 12
DP  - 2021 Oct 23
TI  - Stroke Prevention in Cervical Artery Dissection.
PG  - 182
LID - 10.1007/s11886-021-01603-2 [doi]
AB  - PURPOSE OF REVIEW: Cervical artery dissection (CAD) is rare, yet it is a common 
      cause of stroke in young and middle-aged adults. Historically, some senior 
      clinicians favored anticoagulation in the prevention of stroke due to CAD. 
      Choosing the optimal antithrombotic treatment with either antiplatelet (AP) or 
      anticoagulant (AC) medications remains a challenge. This paper will review the 
      clinical features and imaging of CAD, and the acute treatment and prevention of 
      stroke due to CAD. RECENT FINDINGS: Until 2015, there were no prospective 
      randomized trials in the optimal antithrombotic management of CAD. The Cervical 
      Artery Dissection in Stroke Study (CADISS) trial found that treatment with AC did 
      not lower the risk of subsequent stroke or death at 3 months when compared to AP 
      agents. This led to a paradigm shift in national guidelines. In 2021, The 
      Biomarkers and Antithrombotic Treatment in of Cervical Artery Dissection 
      (TREAT-CAD) trial however did not confirm the non-inferiority of AP therapy in 
      stroke prevention due to CAD. The optimal antithrombotic management for stroke 
      prevention in CAD remains uncertain, while the superiority of anticoagulation has 
      not been established, nor has the non-inferiority of AP agents. The future 
      direction of research should consider early preventative treatment, dual 
      treatment with AP agents, direct oral AC medications, and aggregation of data 
      from existing randomized trials.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Gill, Rick
AU  - Gill R
AUID- ORCID: 0000-0001-6187-018X
AD  - Department of Neurology, Loyola University Chicago, Stritch School of Medicine, 
      Maywood, IL, 560153, USA. rick.gill@lumc.edu.
FAU - Biller, Jose
AU  - Biller J
AD  - Department of Neurology, Loyola University Chicago, Stritch School of Medicine, 
      Maywood, IL, 560153, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211023
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
EIN - Curr Cardiol Rep. 2022 Jan;24(1):65. PMID: 35028822
MH  - Adult
MH  - Anticoagulants/therapeutic use
MH  - Arteries
MH  - Dissection
MH  - Humans
MH  - Middle Aged
MH  - *Platelet Aggregation Inhibitors/therapeutic use
MH  - *Stroke/etiology/prevention & control
OTO - NOTNLM
OT  - Anticoagulation
OT  - Antiplatelet
OT  - Antithrombotic
OT  - Cervical artery dissection
OT  - Stroke
OT  - Thrombolysis
EDAT- 2021/10/24 06:00
MHDA- 2021/10/30 06:00
CRDT- 2021/10/23 12:09
PHST- 2021/08/25 00:00 [accepted]
PHST- 2021/10/23 12:09 [entrez]
PHST- 2021/10/24 06:00 [pubmed]
PHST- 2021/10/30 06:00 [medline]
AID - 10.1007/s11886-021-01603-2 [pii]
AID - 10.1007/s11886-021-01603-2 [doi]
PST - epublish
SO  - Curr Cardiol Rep. 2021 Oct 23;23(12):182. doi: 10.1007/s11886-021-01603-2.